Company

Takeda Pharms U

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 11, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Kazano (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for labeling change to an existing combination antidiabetic product; no clinical trial data or efficacy outcomes reported.

Regulatory UpdateTakeda Pharms U Alogliptin AND Metformin Hydrochloride

APR 23, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Vyvanse (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval of labeling change for Vyvanse (lisdexamfetamine dimesylate); this is a regulatory action, not a clinical trial, and does not report efficacy or comparative benefit data.

Regulatory UpdateLisdexamfetamine Dimesylate Takeda Pharms U